Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Solid Neoplasm|Male Breast Carcinoma|Recurrent Adult Brain Neoplasm|Recurrent Breast Carcinoma|Recurrent Colon Carcinoma|Recurrent Melanoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Carcinoma|Recurrent Rectal Carcinoma|Recurrent Renal Cell Carcinoma|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage IIIA Colon Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIA Rectal Cancer|Stage IIIA Skin Melanoma|Stage IIIB Breast Cancer|Stage IIIB Colon Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIB Rectal Cancer|Stage IIIB Skin Melanoma|Stage IIIC Breast Cancer|Stage IIIC Colon Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Ovarian Germ Cell Tumor|Stage IIIC Rectal Cancer|Stage IIIC Skin Melanoma|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer
Interventions: DRUG: Gamma-Secretase Inhibitor RO4929097|DRUG: Cediranib Maleate|OTHER: Pharmacological Study|OTHER: Laboratory Biomarker Analysis
Sponsor: National Cancer Institute (NCI)